Business Context and Reporting Period
This Form 6-K filing by CollPlant Biotechnologies Ltd. covers the month of August 2026. The report serves to update the registrant's Registration Statement on Form F-3 (File No. 333-297347) regarding the validity of ordinary shares registered for resale.
Key Corporate Action
Following shareholder approval reported on July 29, 2026, the Company increased its authorized share capital from 30,000,000 ordinary shares to 500,000,000 ordinary shares. The par value remains NIS 1.50 per share. This action included an amendment to the Company's Amended and Restated Memorandum and Articles of Association.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a legal update regarding share capital and does not contain financial performance data.
Material Changes
- Authorized Capital Increase: The authorized share count increased significantly from 30 million to 500 million shares.
- Legal Opinion Update: The Company filed an updated opinion from counsel, Goldfarb Gross Seligman & Co., confirming the validity of the ordinary shares registered for resale under the Form F-3.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on operations, specific risks, or contingencies beyond the procedural update of the share capital increase.
Investor Verification Checklist
- Verify the effective date of the amendment to the Memorandum and Articles of Association.
- Confirm the status of the Registration Statement on Form F-3 (File No. 333-297347) following this incorporation by reference.
- Review the attached Exhibit 5.1 for the full legal opinion regarding the validity of the newly authorized shares.